{"prompt": "[\"Ability to comply with the study protocol, in the investigator's judgment\", 'Eastern Cooperative Oncology Group (ECOG; see Appendix 5) performance status', '0 or 1', 'Intact skin at planned site of subcutaneous injections (thigh)', 'LVEF 55% measured by echocardiogram (ECHO) or multiple-gated acquisition', '(MUGA) scan within 28 days of study randomization', 'No major surgical procedure unrelated to breast cancer within 28 days prior to', 'randomization or anticipation of the need for major surgery during the course of study', 'treatment', 'For women of childbearing potential: agreement to remain abstinent (refrain from', 'heterosexual intercourse) or use contraceptive measures, and agreement to refrain from', 'donating eggs, as defined below:', 'Women must remain abstinent or use non-hormonal contraceptive methods with a failure', 'rate of < 1% per year, or 2 effective non-hormonal contraceptive methods during the', 'study treatment periods and for 7 months after the last dose of study treatment. Women', 'must refrain from donating eggs during this same period.', 'A woman is considered to be of childbearing potential if she is post-menarchal, has not', 'reached a post-menopausal state (post-menopausal defined as 12 continuous months', 'of', 'amenorrhea with no identified cause other than menopause), and has not undergone', 'surgical sterilization (removal of ovaries and/or uterus). The definition of childbearing', 'potential may be adapted for alignment with local guidelines or requirements.', 'Examples of non-hormonal contraceptive methods with a failure rate of < 1% per year', 'include bilateral tubal ligation, male sterilization (with appropriate post-vasectomy', 'documentation of the absence of sperm in the ejaculate) and copper intrauterine devices', '(IUDs).', 'The reliability of sexual abstinence should be evaluated in relation to the duration of the', 'clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g.,', 'calendar, ovulation, symptothermal, or post-ovulation methods) and withdrawal are not', 'acceptable methods of contraception.', 'For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a', 'condom, and agreement to refrain from donating sperm, as defined below:', 'With female partners of childbearing potential or pregnant female partners, men must', 'remain abstinent or use a condom during the study treatment periods and for seven', 'months after the last dose of study treatment to avoid exposing the embryo. Men must', 'refrain from donating sperm during this same period.', 'The reliability of sexual abstinence should be evaluated in relation to the duration of the', 'clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g.,', 'calendar, ovulation, symptothermal, or post-ovulation methods) and withdrawal are not', 'acceptable methods of preventing drug exposure.', 'A negative serum pregnancy test must be available prior to randomization for women of', 'childbearing potential (defined as post-menarchal, has not had 12 continuous months', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '43 / Protocol MO40628, Version 12']['of amenorrhea with no identified cause other than menopause, and has not undergone', 'surgical sterilization [removal of ovaries and/or uterus])', '4.1.2', 'Exclusion Criteria', 'Patients who meet any of the following criteria will be excluded from study entry:', 'Cancer-specific criteria', 'Stage IV (metastatic) breast cancer', 'Current or prior history of active malignancy (other than current breast cancer) within the', 'last five years. Appropriately treated non-melanoma skin cancer; in situ carcinomas,', 'including cervix, colon, or skin; or Stage I uterine cancer within the last five years are', 'allowed.', 'A patient with previous invasive non-breast cancer is eligible provided he/she has been', 'disease free for more than five years.', 'Previous systemic therapy (including chemotherapy, immunotherapy, HER2-targeted', 'agents, endocrine therapy [selective oestrogen receptor modulators, aromatase', 'inhibitors], and antitumor vaccines) for treatment or prevention of breast cancer, except', 'neoadjuvant Perjeta, Herceptin and chemotherapy for current breast cancer', 'General criteria:', 'Investigational treatment within four weeks of enrolment', 'Serious cardiac illness or medical conditions including, but not confined to, the following:', '- History of NCI CTCAE v4.0 Grade 3 symptomatic congestive heart failure (CHF) or', 'New York Heart Association (NYHA) Class II', '- High-risk uncontrolled arrhythmias (i.e., atrial tachycardia with a heart rate 100/min', 'at rest, significant ventricular arrhythmia [ventricular tachycardia], or higher-grade', 'atrioventricular [AV]-block, such as second-degree AV-block Type 2 [Mobitz II] or', 'third-degree AV-block)', '- Serious cardiac arrhythmia or severe conduction abnormality not controlled by', 'adequate medication', '- Angina pectoris requiring anti-angina medication', '- Clinically significant valvular heart disease', '-', 'Evidence of transmural infarction on electrocardiogram (ECG)', '- Evidence of myocardial infarction within 12 months prior to randomization', '- Poorly controlled hypertension (e.g., systolic > 180 mm Hg or diastolic > 100 mmHg)', 'History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias, such as', 'structural heart disease (e.g., severe left ventricular systolic dysfunction [LVSD], left', 'ventricular hypertrophy), coronary heart disease (symptomatic or with ischemia', 'demonstrated by diagnostic testing), clinically significant electrolyte abnormalities (e.g.,', 'hypokalaemia, hypomagnesemia, hypocalcaemia), or family history of sudden', 'unexplained death or long QT syndrome', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '44 / Protocol MO40628, Version 12']\n\n###\n\n", "completion": "END"}